Long-Term Efficacy of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy by National Amyloidosis Centre stage
European Journal of Heart Failure · 01.12.2025 · 27 (12) · 2998-3009
DOI: 10.1002/ejhf.3696 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Heart Failure, online erschienen am 09.06.2025. Verfasst von Thibaud Damy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Henri Mondor University Hospital, Créteil, France. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Benzoxazoles, Cardiomyopathies. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Aims
Tafamidis is an approved treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) based on the 30-month Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). This post-hoc analysis evaluated outcomes in ATTR-ACT and its long-term extension study (LTE) by baseline National Amyloidosis Centre (NAC) stage. Methods and results Patients received either the approved dose of tafamidis 80 mg or placebo in ATTR-ACT and tafamidis in the LTE. All-cause and cardiovascular (CV)-related mortality, CV-related hospitalizations, and Kansas City Cardiomyopathy Questionnaire overall summary and clinical summary (KCCQ-OS/CS) scores were assessed up to 90 months of follow-up. Of 353 patients, 350 were evaluable for NAC staging. At baseline, 42%, 38%, and 20% were NAC stage I, II, and III, respectively. At the end of study, all-cause mortality was lower in the continuous tafamidis versus placebo to tafamidis groups at NAC stages I (36% vs. 61%; hazard ratio [HR] 0.43, p < 0.001) and II (55% vs. 74%; HR 0.51, p = 0.003); with a numerical trend at stage III (69% vs. 88%; HR 0.75, p = 0.298). Survival curves diverged early in patients at NAC stage I, but later at higher stages. Similar patterns were observed for CV-related mortality. Continuous tafamidis versus placebo to tafamidis groups at NAC stages I/II had lower CV-related hospitalization rates and frequently smaller declines in KCCQ-OS/CS scores over follow-up; with favourable trends at stage III.
Conclusions
Tafamidis treatment reduced the risk of mortality and hospitalization in patients with NAC stages I/II ATTR-CM, with favourable trends at stage III. This illustrates the importance of early diagnosis and initiation of disease-modifying therapy. Clinical Trial Registration: ClinicalTrials.gov, NCT01994889, NCT02791230.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Henri Mondor University Hospital, Créteil, France.
- Pfizer Inc, Groton, CT, USA.
- Division of Cardiology, Columbia University Irving Medical Center, New York, NY, USA.
- National Amyloidosis Centre, Division of Medicine, University College London, London, UK.
Förderung
- Pfizer
Zitieren
APA
Damy, T., Wang, R., Maurer, M. S., Gillmore, J. D., & Fontana, M. (2025). Long-Term Efficacy of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy by National Amyloidosis Centre stage. European Journal of Heart Failure, 27(12), 2998-3009. https://doi.org/10.1002/ejhf.3696
Vancouver
Damy T, Wang R, Maurer MS, Gillmore JD, Fontana M. Long-Term Efficacy of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy by National Amyloidosis Centre stage. European Journal of Heart Failure. 2025;27(12):2998-3009. doi:10.1002/ejhf.3696
BibTeX
@article{Damy2025,
author = {Damy, Thibaud and Wang, Rong and Maurer, Mathew S and Gillmore, Julian D and Fontana, Marianna},
title = {Long-Term Efficacy of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy by National Amyloidosis Centre stage},
journal = {European Journal of Heart Failure},
year = {2025},
volume = {27},
number = {12},
pages = {2998--3009},
doi = {10.1002/ejhf.3696}
}
EUVIMED